"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.

Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) ...

Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with ...

The U.S. Federal Trade Commission on Tuesday published the second part of its investigation into how prescription drug ...

Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...

The Federal Trade Commission has published a report that found pharmacy benefit managers Caremark Rx LLC (CVS), Express Scripts and OptumRx marked up numerous specialty generic drugs by ...

Expansion into the supply chain side of the drug industry is ... there has traditionally been a lack of uptake in biosimilars on PBM formularies, likely due to less favorable PBM rebate models ...

A key provision in the new legislation could affect compensation for brokers or consultants who help employers hire pharmacy ...

At issue is the role pharmacy benefit mangers play in taking large discounts on drugs that advocates say are not passed along ...